sanostem

  • 1615 South Street, 93304

Our Progenitor Cells

Our Progenitor Cells

Our Progenitor Cells

Ischemia-tolerant mesenchymal stem cells, or itMSCs, are “trophic” cells that move throughout the body and release growth hormones and proteins into injured tissue, saving the damaged cells from dying and establishing the ideal environment for the newly mobilized cells to multiply and heal. Sanostem’s itMSCs are grown utilizing our in-house technology after being isolated from donated bone marrow.
Ischemia-tolerant neural stem cells, or itNSCs, are multipotent, largely undifferentiated cells that produce the primary phenotypes of nervous system cells. Donated brain tissue is used to extract Sanostem’s itNSCs, which are subsequently grown utilizing our patented method.
ItMSCs and itNSCs are produced by Sanostem for use in FDA-approved clinical trials in the United States. Furthermore, we provide our progenitor cells to geographic distributors for use in research through ThermoFisher Scientific, our exclusive distribution partner, and for clinical trials that have been authorized by international regulatory bodies.

Our Progenitor Cells

Ischemia-tolerant mesenchymal stem cells, or itMSCs, are “trophic” cells that move throughout the body and release growth hormones and proteins into injured tissue, saving the damaged cells from dying and establishing the ideal environment for the newly mobilized cells to multiply and heal. SanoStem’s itMSCs (SanoMSC) are grown utilizing our in-house technology after being isolated from 1 single donated bone marrow.

Ischemia-tolerant neural stem cells, or itNSCs, are multipotent, largely undifferentiated cells that produce the primary phenotypes of nervous system cells. Donated brain tissue is used to extract SanoStem’s itNSCs, which are subsequently grown utilizing our patented method.

ItMSCs and itNSCs are produced by SanoStem for use in FDA-approved clinical trials in the United States. Furthermore, we provide our progenitor cells to geographic distributors for use in research through ThermoFisher Scientific, our exclusive distribution partner, and for clinical trials that have been authorized by international regulatory bodies.

The following characteristics are among the unique qualities of SanoStem’s itMSCs (SanoMSC) and itNSCs (SanoNSC):

Ischemia tolerant: To counteract ischemia circumstances, SanoStem produces its progenitor cells in a hypoxic environment. ItMSCs, for instance, release more of the vital cytokines that promote healing, like VEGF and SDF-1. SDF-1 aids in the mobilization of the patient’s own progenitor cells, whereas VEGF is essential for the development of new blood vessels.

Immune privileged: Progenitor cells from SanoStem lack the HLA-DR antigen proteins, which could lead to rejection. Using flow cytometry analysis, each batch’s lack of HLA-DR expression is verified. During treatment, no immunosuppressive medications are needed.

Documented safety: Endogenous viruses, adventitious agents, bacteria, mycoplasma, endotoxins, acute and chronic toxicity, and tumorigenicity are all thoroughly tested for in the cells.

Established purity: SanoStem upholds strict standards for every relevant biological sign that denotes the purity of cells. Moreover, lot-to-lot repeatability is indicated by thorough batch testing.

Verified potency: Progenitor cells need to release the right growth factors, cytokines, and hormones in order to function well in vivo. Additionally, the progenitor cells must exhibit the capacity to develop into particular tissue types, such as cartilage, neurons, or bone. Before releasing its progenitor cells for therapeutic use, SanoStem makes sure they fulfill the necessary requirements.

The Allogeneic Progenitor Cell Difference

Autologous and allogeneic cells are the two cell types now being studied for progenitor cell therapy for degenerative disorders. The patient receiving treatment provides the autologous progenitor cells. They are surgically removed, enlarged, and then given back to the original patient. Organ donations or healthy volunteers are the sources of allogeneic progenitor cells. These cells are grown and preserved for use in a variety of illnesses in the future. The competitive benefits of SanoStem’s allogeneic progenitor cell products are as follows:

Reproducibility: With stringent production control over cell quality and performance, SanoStem can already manufacture over 500,000 doses of itMSCs from a single donor and 180,000 doses of itNSCs from a single different donor.
Immune Privilege: Since autologous cells come from the same organism that gets the stem cells, there is less chance of an immunological reaction, making them more immune privileged. On the other hand, the host’s expression of HLA-DR receptors on the cell surface is the primary cause of allogeneic stem cell rejection and clearance, which may result in an immunological reaction from the host body. By cultivating itMSCs and itNSCs in low-oxygen environments, SanoStem lowers the HLA-DR level to less than 2%, lowering the likelihood of an immunological reaction.
Cost: Compared to allogeneic therapy, autologous stem cell therapy is significantly more costly. While autologous cells must be extracted from the patient through invasive surgery, tested, expanded separately, and then reintroduced into the patient, allogeneic cells are readily available and have previously undergone testing.
Scalability: With hundreds of thousands of treatment doses derived from a healthy donor sample, SanoStem’s itMSCs and itNSCs are incredibly scalable. Because autologous cells must be surgically extracted from each patient, they are not scalable.
Scroll to Top